

**Supplementary material 6: Meta-regression and subgroup analysis
for Aβ42/Aβ40, P-tau 181, and NFL in diagnostic meta.**

Aβ42/Aβ40							
Variable	Study	LRT Chi ²	p	Sensitivity	p	Specificity	p
Age	6	0	0.05	0.86 (0.77 - 0.92)	0.99	0.44 (0.22 - 0.68)	0.76
Female%	6	0.1	0.95	0.86 (0.80 - 0.91)	0.98	0.48 (0.25 - 0.73)	0.99
Follow up	6	1.89	0.39	0.87 (0.79 - 0.92)	0.74	0.53 (0.24 - 0.80)	0.84
MMSE	6	3.35	0.19	0.82 (0.54 - 0.95)	0.6	0.81 (0.45 - 0.82)	0.79
APOE	5	40.02	0	0.90 (0.85 - 0.94)	0.89	0.36 (0.29 - 0.44)	0.63
MCI type	6	5.11	0.08				
aMCI	4			0.89 (0.83 - 0.95)	0.37	0.51 (0.19 - 0.82)	0.79
MCI	2			0.83 (0.71 - 0.94)		0.43 (0.00 - 0.87)	
Study type	6	7.54	0.02				
Community	2			0.81 (0.70 - 0.93)	0.01	0.79 (0.61 - 0.98)	0.01
Clinical	4			0.88 (0.82 - 0.94)		0.31 (0.14 - 0.48)	
Method							
ELISA	1			0.86 (0.71 - 1.00)	0.53	0.70 (0.20 - 1.00)	0.3
SIMOA	2			0.95 (0.91 - 0.99)	0.64	0.22 (0.01 - 0.44)	0.05
MS	1			0.63 (0.26 - 0.99)	0.06	0.87 (0.64 - 1.00)	0.02
xMAP	1			0.85 (0.68 - 1.00)	0.30	0.28 (0.20 - 0.76)	0.29
Elecys	1			0.81 (0.66 - 0.97)	0.06	0.63 (0.04 - 1.00)	0.51

P-tau 181							
Variable	Study	LRT Chi ²	p	Sensitivity	p	Specificity	p
Age	8	4.17	0.12	0.81 (0.72 - 0.88)	0.86	0.79 (0.73 - 0.84)	0.51
Female%	8	0.04	0.98	0.88 (0.06 - 1.00)	0.85	0.74 (0.02 - 1.00)	0.95
Follow up	9	1.86	0.4	0.83 (0.75 - 0.88)	0.61	0.75 (0.66 - 0.82)	0.54
MMSE	7	3.37	0.19	0.93 (0.68 - 0.99)	0.3	0.59 (0.36 - 0.79)	0.08
APOE	6	0.49	0.78	0.97 (0.06 - 1.00)	0.52	0.82 (0.05 - 1.00)	0.94
MCI type	7	1.74	0.42				
aMCI	5			0.83 (0.76 - 0.89)	0.39	0.76 (0.68 - 0.83)	0.01
MCI	2			0.75 (0.61 - 0.89)		0.84 (0.74 - 0.95)	
Study type	8	8.66	0.01				
Community	1			1.00 (1.00 - 1.00)	0	0.52 (0.34 - 0.69)	0
Clinical	7			0.80 (0.74 - 0.86)		0.80 (0.75 - 0.84)	
Method							
SIMOA	5			0.84 (0.77 - 0.92)	0.1	0.75 (0.66 - 0.85)	0.01
MS	1			0.89 (0.78 - 1.00)	0.89	0.77 (0.57 - 0.97)	0.39
MSD	2			0.76 (0.64 - 0.89)	0.01	0.85 (0.74 - 0.95)	0.44
Lumipulse	1			0.69 (0.48 - 0.90)	0.04	0.76 (0.55 - 0.96)	0.34

NFL

Variable	Study	LRT Chi ²	p	Sensitivity	p	Specificity	p
Female%	4	0.68	0.71	0.93 (0.04 - 1.00)	0.7	0.89 (0.01 - 1.00)	0.63
Follow up	4	11.21	0	0.78 (0.68 - 0.85)	0.7	0.70 (0.63 - 0.77)	0.1
MCI type	4	0.97	0.61				
aMCI	3			0.76 (0.66 - 0.87)	0.03	0.61 (0.44 - 0.79)	0.81
MCI	1			0.85 (0.74 - 0.95)		0.63 (0.32 - 0.94)	
Study type	4	5.89	0.05				
Community	1			0.69 (0.58 - 0.80)	0	0.64 (0.36 - 0.93)	0.99
Clinical	3			0.84 (0.77 - 0.91)		0.61 (0.43 - 0.79)	